KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)’s earnings report is anticipated on December, 13., as reported by Faxor. Analysts have anticipation on stock’s earnings per share of $-0.51. That’s down 2.00 % from last year’s $-0.5 earnings per share. After $-0.47 EPS report last quarter, Wall Street now forecasts 8.51 % negative EPS growth of KalVista Pharmaceuticals, Inc.. The stock decreased 0.16% or $0.03 during the last trading session, reaching $18.97.Currently KalVista Pharmaceuticals, Inc. is uptrending after 81.98% change in last November 9, 2017. KALV has also 29,366 shares volume. KALV outperformed by 66.36% the S&P500.
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors.The firm is worth $325.90 million. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.Currently it has negative earnings. The Company’s products include KVD001, an intravitreally administered plasma kallikrein inhibitor that is in Phase II clinical trials for the treatment of DME; and KVD900, a potent inhibitor of plasma kallikrein, which is in Phase I clinical trial for treating HAE.
More recent KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) news were posted by Nasdaq.com, Seekingalpha.com and Streetinsider.com. The first one has “Report: Exploring Fundamental Drivers Behind Syndax Pharmaceuticals, Arconic, Del Taco Restaurants, Aerohive …” as a title and was posted on October 18, 2018. The next is “Premarket analyst action – healthcare” on October 15, 2018. And last was posted on October 15, 2018, called “Stifel Starts Kalvista Pharmaceuticals Inc (KALV) at Buy”.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.